Skip to main content

Table 3 Cumulative malaria case incidence at 3, 6, 12, and 16 months after MDA

From: A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission

 

Malaria cases

Cumulative incidence (cases/1000 population; range between shehias)

 

Time period

Intervention (N = 10,944)

Control (N = 12,307)

Intervention

Control

p value

Baseline

 6 months (May–Nov 2015)

128

126

11.7; 7.7–16.1

10.2; 6.4–32.8

0.130

 12 months (May 2015–April 2016)

150

146

13.7; 9.8–19.6

11.9; 7.5–36.8

0.105

Post-MDA

 3 months (May–Aug 2016)

31

41

2.8; 0.0–10.3

3.3; 0.9–8.0

0.721

 6 months (May–Nov 2016)1

43

52

3.9; 0.0–13.1

4.2; 2.1–8.0

0.442

 12 months (May 2016–April 2017)

58

71

5.3; 0.0–13.1

5.8; 3.1–10.4

0.382

 16 months (May 2016–Aug 2017)

143

208

13.1; 5.4–28.0

16.9; 6.7–31.8

0.130

Post-MDA cases without travel history

 3 months (May–Aug 2016)

18

23

1.6; 0.0–9.3

1.9; 0.0–8.0

0.716

 6 months (May–Nov 2016)

22

29

2.0; 0.0–11.2

2.4; 0.9–8.0

0.277

 12 months (May 2016–April 2017)

31

41

2.8; 0.0–11.2

3.3; 1.1–8.0

0.315

 16 months (May 2016–Aug 2017)

109

160

10.0; 5.4–26.1

13.0; 2.7–30.8

0.279

  1. 1Primary outcome